In Section C, members will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually sickness progression or the contributors are unable to tolerate the study drugs. - Participant eaten grapefruit or grapefruit products within 3 days previous to the https://vasilievichg443seq7.iamthewiki.com/user